ADAM17 and colorectal carcinoma: In vivo drug trials demonstrated that these ADAM17 inhibitors significantly reduced the EMT-HCT116 exosome-induced decrease in VE-cadherin at the invasive front of CRC tumors (Fig. 6b, c); moreover, treatment with these inhibitors reduced the number of CTCs in mouse blood (Fig. 6c) and reduced the proportion of mice with both lung and liver metastasis (Fig. S6b).